share_log

Avenue Therapeutics | EFFECT: Others

Avenue Therapeutics | EFFECT: Others

Avenue Therapeutics | EFFECT:其他
美股sec公告 ·  05/13 06:04
Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc. has announced the effectiveness of a Form S-3 filing with the United States Securities and Exchange Commission (SEC). The notice of effectiveness, which is a significant step for the company, was issued on May 10, 2024, at 4:00 PM. This form is typically used by companies to register securities for potential future offerings. The filing, under the file number 333-279125, indicates that Avenue Therapeutics has met the SEC's requirements to potentially offer securities to the public.
Avenue Therapeutics, Inc. has announced the effectiveness of a Form S-3 filing with the United States Securities and Exchange Commission (SEC). The notice of effectiveness, which is a significant step for the company, was issued on May 10, 2024, at 4:00 PM. This form is typically used by companies to register securities for potential future offerings. The filing, under the file number 333-279125, indicates that Avenue Therapeutics has met the SEC's requirements to potentially offer securities to the public.
Avenue Therapeutics, Inc.已宣布向美国证券交易委员会(SEC)提交的S-3表格的生效。生效通知于2024年5月10日下午4点发布,这是公司迈出的重要一步。公司通常使用此表格来注册证券,以备将来可能的发行。该文件编号为333-279125,表明Avenue Therapeutics已满足美国证券交易委员会可能向公众发行证券的要求。
Avenue Therapeutics, Inc.已宣布向美国证券交易委员会(SEC)提交的S-3表格的生效。生效通知于2024年5月10日下午4点发布,这是公司迈出的重要一步。公司通常使用此表格来注册证券,以备将来可能的发行。该文件编号为333-279125,表明Avenue Therapeutics已满足美国证券交易委员会可能向公众发行证券的要求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息